News and Trends 16 Nov 2016 New Private Placement to Boost the Profitable Therapeutic Antibody Market MorphoSys has announced a private placement of shares to raise funds for its antibody therapy programs. With this push, the company is solidifying its position as a leader in the… November 16, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jan 2019 Sanofi Obtains License for French Company’s Antibody Engineering Platform …lead antibody is due to enter the clinic next year for the treatment of solid tumors. The company’s second lead candidate is aimed at blood cancers such as multiple myeloma,… January 15, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 6 Nov 2017 German Biotech Teams Up with BioNTech to Boost Antibody Development MAB Discovery and BioNTech are working together to push through the development of new antibody therapeutics using MAB’s technology platform. MAB Discovery creates monoclonal antibodies by stimulating natural antibody maturation… November 6, 2017 - 1 minutemin - By Alex Dale Share WhatsApp Twitter Linkedin Email
Best in Biotech 20 Feb 2018 Money, Money, Money! Europe’s Best-Funded Biotechs in 2018 …core focus is the discovery and development of new antibody-based drugs for the treatment of cancer, immune disorders, and inflammatory diseases. Novimmune’s innovation lies in their monoclonal and bispecific antibody… February 20, 2018 - 11 minutesmins - By Karen O’Hanlon Cohrt Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jun 2022 New COVID antibody cocktail developed …in live virus neutralization assays. The cocktail and each antibody also outperformed other monoclonal treatments currently approved or authorized by the FDA and EMA, particularly against Omicron. “Antibody cocktails will… June 8, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Nov 2019 ViiV Healthcare Licenses Long-Acting Antibody to Attack Hidden HIV …of Health, US. ViiV Healthcare’s majority shareholder, the pharma company GSK, licensed the antibody from the US organization, and ViiV Healthcare will launch a phase IIa trial of the antibody… November 22, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 30 Nov 2017 Cha-Ching! Danish Biotech Gets $5M as Antibody-Antibiotic Combo Enters Phase Ib …Phase Ib trial assessing the safety and tolerability of Genentech’s candidate, DSTA4637S, which combines Symphogen’s antibody with an antibiotic agent. Staphylococcus aureus infections are particularly deadly, with an annual incidence… November 30, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 23 Feb 2017 In the Age of Biological Therapeutics, Chemists move to ADCs …ADCs include the absence of data on unconjugated antibody testing, criteria for an acceptable amount of unconjugated antibody, and data relating to the drug-antibody ratio. Images from the author … February 23, 2017 - 4 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
In Depth 26 Jul 2023 Antibody drug conjugates: BiVictriX drives a new era in cancer medicine …a monoclonal antibody – which binds to the cancer protein in a cell – attached to a linker, which delivers the anticancer drug once the antibody latches on to the… July 26, 2023 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
More News! 20 Sep 2017 New UK Team will develop Next-Generation Antibody-Drug Conjugates for Cancer Glythera and IONTAS have partnered to develop next-generation antibody-drug conjugates that are less toxic and more potent against difficult-to-treat tumors. Glythera has teamed up with antibody developer IONTAS to work… September 20, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
In Depth 1 Aug 2024 CureVac: From a failed drug to a €1.45 billion deal …the race with its first-generation COVID-19 vaccine, CVnCoV, it did not come first, and didn’t even finish the race. Indeed, CureVac faced significant setbacks with its COVID candidates, allowing Moderna… August 1, 2024 - 8 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Sponsored by Hub Organoids 12 Jul 2022 The organoid era: bringing patient-relevant preclinical models to the lab …in a large patient sample.” This led to the identification of a promising candidate. “An extended screen with CRC organoid models showed that the newly identified antibody effectively blocked tumor… July 12, 2022 - 7 minutesmins - By Sudha Sundaram Share WhatsApp Twitter Linkedin Email